I outline four reasons why bioinformaticians are newly enabled to drive the questions in primary medical discovery: public availability of data, intersection of data across experiments, commoditization of methods, and streamlined validation.
The distribution derived in this study can be used as a bench mark against which to evaluate LOD50 data generated in future studies of detection methods for Salmonella in foods and potentially offers a possible way to streamline method validation study experimental design.
Besides maintaining the key benefits of culture tests, the rapid method presented here should streamline regulatory validation since it is based on the same underlying principles and procedures as the regulatory gold standard.
Accordingly, this tool has the potential to significantly streamline the verification and validation (V and V) processes in NRS code development environments which are characterized by rapidly evolving software, many contributing developers and a large and growing body of validation data.
Close collaboration between pharmaceutical companies, biotechnology companies and academic institutions during the many intricate phases of drug discovery is necessary to address the need to co-ordinate and streamline target discovery and validation activities, which typically take much longer than anticipated.
Those who apply their research to publicly available data, commoditized tools, and streamlined paths through validation will be able to create novel diagnostics and discover fundamental causes of disease as targets for therapies.
Moving ahead, cooperation between the groups collecting biospecimens and generating genome-wide data from large numbers of patients with PBC will be essential, not only to increase power for fine mapping and future studies of rare variants and epistasis; but to streamline efforts to perform functional validation of novel discoveries.
Together, these innovations are poised to streamline the process of discovery and preclinical validation of targets that, when inhibited, synergise with OVT.
We used density peak clustering as primary streamline cluster algorithm, and Silhouette algorithm as the cluster validation algorithm to select reasonable cluster number, and the results of different clustering algorithms were compared.
Fragment based drug discovery (FBDD) has played an important role in the past decade, helping in many cases to streamline the complex process of drug discovery from target validation to new drug application.
tDAR is able to operate at scale by performing only technical validation and streamlining data deposition with a minimum of mandatory description.
